Moroi S E, Gottfredsdottir M S, Schteingart M T, Elner S G, Lee C M, Schertzer R M, Abrams G W, Johnson M W
W.K. Kellogg Eye Center, University of Michigan Medical Center, Ann Arbor 48105, USA.
Ophthalmology. 1999 May;106(5):1024-9. doi: 10.1016/S0161-6420(99)00528-X.
To identify coexisting ocular diagnoses in a case series of eyes that developed cystoid macular edema (CME) associated with latanoprost therapy.
Retrospective observational case series.
Seven eyes of seven patients who developed CME possibly associated with latanoprost treatment were studied.
When these patients, all of whom were treated with latanoprost in addition to other glaucoma medications, described blurred vision or eye irritation, ocular examination revealed CME, which was confirmed by fluorescein angiography. Latanoprost was discontinued, and in three cases topical corticosteroids and nonsteroidal anti-inflammatory agents were used to treat the CME.
Visual acuity and intraocular pressure were determined before latanoprost use began, during therapy, and after latanoprost use ceased. In these cases, resolution of CME was documented clinically after discontinuing latanoprost.
Clinically significant CME developed after 1 to 11 months of latanoprost treatment, with an average decrease of 3 lines in Snellen visual acuity. Intraocular pressure decreased an average of 27.9% during treatment. Cystoid macular edema was confirmed in all cases by fluorescein angiography. In these seven patients, the following coexisting ocular conditions may have placed these eyes at risk for prostaglandin-mediated blood-retinal barrier vascular insufficiency: history of dipivefrin-associated CME, epiretinal membrane, complicated cataract surgery, history of macular edema associated with branch retinal vein occlusion, history of anterior uveitis, and diabetes mellitus. In all cases, the macular edema resolved following discontinuation of latanoprost, in some instances with concomitant use of steroidal and nonsteroidal anti-inflammatory agents.
In this case series of pseudophakic, aphakic, or phakic eyes, the temporal relationships between the use of latanoprost and developing CME, and the resolution of CME following cessation of the drug, suggest an association between latanoprost and CME. In all cases, coexisting ocular conditions associated with an altered blood-retinal barrier were present.
在一组发生与拉坦前列素治疗相关的黄斑囊样水肿(CME)的病例中,确定并存的眼部诊断。
回顾性观察病例系列。
研究了7例患者的7只眼睛,这些眼睛发生了可能与拉坦前列素治疗相关的CME。
这些患者除了使用其他青光眼药物外均接受拉坦前列素治疗,当他们出现视力模糊或眼部刺激症状时,眼部检查发现了CME,荧光素血管造影证实了这一情况。停用拉坦前列素,3例患者使用局部皮质类固醇和非甾体类抗炎药治疗CME。
在开始使用拉坦前列素之前、治疗期间以及停用拉坦前列素之后测定视力和眼压。在这些病例中,停用拉坦前列素后临床上记录了CME的消退情况。
拉坦前列素治疗1至11个月后出现具有临床意义的CME,Snellen视力平均下降3行。治疗期间眼压平均下降27.9%。所有病例荧光素血管造影均证实存在黄斑囊样水肿。在这7例患者中,以下并存的眼部疾病可能使这些眼睛面临前列腺素介导的血视网膜屏障血管功能不全的风险:双匹夫林相关CME病史、视网膜前膜、复杂白内障手术、视网膜分支静脉阻塞相关黄斑水肿病史、前葡萄膜炎病史和糖尿病。所有病例中,停用拉坦前列素后黄斑水肿均消退,在某些情况下同时使用了类固醇和非甾体类抗炎药。
在这个假晶状体、无晶状体或有晶状体眼睛的病例系列中,拉坦前列素使用与CME发生之间的时间关系,以及停药后CME的消退情况,提示拉坦前列素与CME之间存在关联。所有病例中均存在与血视网膜屏障改变相关的并存眼部疾病。